Improved safety and effectiveness of imaging predicted for MR mammography by Laderoute, M P
Letter to the Editor
Improved safety and effectiveness of imaging predicted for MR
mammography
MP Laderoute*,1
1Blood Zoonotics Unit, Blood Safety Surveillance and Health Care Acquired Infections Division, Centre for Infectious Disease Prevention and Control,
Population and Public Health Branch, Health Canada, Tunney’s Pasture AL 0601E2, Ottawa, Ontario Canada K1A 0L2
British Journal of Cancer (2004) 90, 278–279. doi:10.1038/sj.bjc.6601442 www.bjcancer.com
& 2004 Cancer Research UK
                
Sir,
The recent review article by Kneeshaw et al (2003) in the British
Journal of Cancer regarding advances made in breast imaging by
magnetic resonance is very encouraging and its expedited entry into
routine clinical practice should be supported. This is not only due to
its anticipated enhanced sensitivity and usefulness, but potentially
also for its safety, particularly as may apply to radiation hypersensi-
tivities such as female carriers of ataxia telangiectasia (AT).
Ataxia telangiectasia is a genetic cancer predisposition syn-
drome involving the overexpression of alpha-fetoprotein, immu-
nosuppression of the host, advanced ageing, and a radiation
hypersensitivity where AT homozygotes generally succumb to
infection or to lymphoma before reaching adulthood (reviewed in
Becker-Catania and Gatti, 2001). Female AT heterozygotes are at
an increased risk of breast cancer, but this is usually detected after
the age of 40 years (Swift et al, 1991; Swift, 2001,). The issue of
safety of ionising radiation used for breast cancer screening has
been previously raised for AT heterozygotes (Swift et al, 1991).
About 1% of the population carries the genetic marker for AT, and
8–10% of all breast cancers appear to be AT heterozygotes
(reviewed in Swift, 2001). This indicates the use of nonionising
modes of breast imaging could make a significant impact on the
incidence of breast cancers. However, other evidence suggests
these potential benefits might also be extended into the general
female population.
A number of years ago while investigating the molecular biology
of the AT radiation hypersensitivity, it was discovered that
radioresistant DNA synthesis (RDS), the molecular signature of
the radiation hypersensitivity of AT, could be modulated
(Mirzayans et al, 1995; Mirzayans and Paterson, 2001). When
c-myc and alpha-fetoprotein became implicated in the RDS
phenotype (Laderoute, unpublished findings), oestrogen was
tested for its ability to induce RDS in cells derived from normal
individuals. As shown in Figure 1, RDS was induced by estradiol
(E2) but not progesterone in a dose-responsive fashion in
lymphoblastoid cell lines (LCLs) derived from normal individuals
(panel A). The induction was specific to oestrogen as it was
blocked in the presence of an excess of tamoxifen (panel C), an
oestrogen antagonist (Laderoute, 1998). Furthermore, additional
experiments showed the RDS assay could be geared to easily detect
low dose ionising radiation exposures around 1rad or less in
radiation hypersensitive cells such as those from AT individuals or
AT heterozygotes (Laderoute, 1998). These results raised the
possibility that breast imaging techniques using low-dose
ionising radiation may induce breast cancers or cause existing
breast tumours to progress, if the circulating levels of
oestrogen are elevated in women at the time of mammography
exposure. This phenomenon might help explain the reduced
benefits in the under 50 years age-at-entry group reported in
mammogram clinical trials (Miller et al, 1992, 2002), the increased
incidence of breast cancer with mammogram screening among
45- to 64- year olds not accountable by earlier detection (White
et al, 1990), and the lack of impact of mammography screening for
reducing breast-cancer mortality overall (Gotzsche and Olsen,
2000).
It remains to be seen if the incidence of breast cancer returns to
the premammogram screening rates of the 1960s and 1970s, as
ionising radiation-based breast imaging technologies are replaced
by MR imaging and as women decline hormone replacement
therapies. One might also expect survival to again correlate
inversely with tumour size, which is why early breast cancer
imaging methods were introduced in the first place.
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Figure 1 Estrogen specifically induces RDS in cells from normal individuals. Radioresistant DNA synthesis (RDS) measures the relative failure of cells from
AT individuals to inhibit DNA synthesis at 1h following ionising radiation exposures when compared to responses in normal cells that are conducted in
parallel. To demonstrate this, the thymidine incorporation following ionising radiation is expressed as a percentage of that found when the cells are mock
irradiated (see Laderoute (1996) for more details on methods). Panels (A) and (B) were conducted in parallel and as can be seen, the AT LCL labelled VKE
show about 70% of the rate of DNA synthesis when the cells are not irradiated representing a 30% inhibition (see left side of panel B). In panel A, the LCLs
labelled NAT8 derived from a normal individual has a postirradiation rate of about 45% of the level of DNA synthesis (left side of panel A) representing an
inhibition of about 55%. The difference between the two (55% 30%¼25%) represents RDS. As also shown in panel A, when the LCLs from normal
individuals are treated overnight with oestrogen but not progesterone before performing the RDS assay, there is a reduced ability to inhibit DNA synthesis
following irradiation, and this effect is proportional to the concentrations of oestrogen, implying a dose response. In panel B, we see in AT LCLs that RDS is
relatively independent of added hormone. In the bottom panels (C and D), also conducted in parallel, it is that shown an excess of 10
 6 M of tamoxifen
added to the cells before estradiol is added, blocks the induction of RDS in LCLs from normals (panel C). In AT LCLs (panels B and D) tamoxifen or
estrogen does not appreciably affect RDS except that at 10
 7 M of oestrogen there seems to be some competition by tamoxifen. This may be consistent
with the notion that genes implicated in RDS may have oestrogen response elements and which is also implicated by the results given in panels A and C.
The dose rate was 68.9cGymin
 1 and cells were exposed to 2Gy. The methods have been detailed earlier (Laderoute, 1996). Steroids were purchased
from Sigma and stock solutions (10
 2 M) were made in 70% ethanol immediately prior to dilution for addition to phenol red-free medium. Estradiol (E2) is
an active version of oestrogen commonly used for in vitro experiments. Results are the means of triplicates and variance did not exceed 10%. The results are
representative of three similar experiments. (Reproduced by kind permission of University of Ottawa Press from Laderoute, 1998).
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